WeVote
Log In

Bill

Bill

HR 6789

To amend title 18, United States Code, to require the Bureau of Prisons to ensure the availability of opioid antagonists at Federal correctional facilities.

119th Congress Introduced by Valerie Foushee and 2 co-sponsors

Requires the Bureau of Prisons to ensure opioid antagonists (like naloxone) are available at all federal prisons to improve overdose response for inmates and staff.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 6789

Summary of HR 6789 (2025)

Overview

HR 6789 is a bill introduced in the U.S. House of Representatives on December 17, 2025. Its stated purpose is to amend title 18 of the United States Code to require the Bureau of Prisons (BOP) to ensure the availability of opioid antagonists at Federal correctional facilities. The measure was referred on the same day to the House Judiciary Committee.

Purpose and Intent

  • Ensure that opioid antagonists are readily available at all Federal correctional facilities.
  • Improve immediate response options for suspected opioid overdoses within federal prisons, protecting inmate and staff safety.

Key Provisions (as described)

  • Amend title 18, U.S. Code: The bill would add a requirement for the Bureau of Prisons to ensure availability of opioid antagonists (e.g., naloxone or similar agents) at federal correctional facilities.
  • Availability and access: Implicit expectations include that these antagonists be accessible to trained staff (and potentially inmates) in appropriate locations within facilities, with protocols for deployment during overdose events.
  • Training and protocols: While not explicitly stated in the bill summary, such legislation typically accompanies training requirements for staff on recognizing overdoses and administering the antagonists, as well as standard operating procedures for medical responses.

Note: The provided bill description does not enumerate exact quantities, locations, storage requirements, training mandates, or funding provisions. If enacted, the implementing details would be defined in committee reports and accompanying regulations.

Affected Parties and Impacts

  • Federal inmates and detainees: Potentially enhanced access to life-saving medication in overdose situations.
  • Federal correctional facility staff: Likely obligations to carry, access, and administer/coordinate use of opioid antagonists, along with training requirements.
  • Bureau of Prisons: Additional compliance, procurement, inventory management, and potential budget considerations to fund and stock the antagonists and related training.

Procedural and Timeline Aspects

  • Introduced: December 17, 2025.
  • Status: Referred to the House Committee on the Judiciary on the same day.
  • Next steps (typical): If advanced, potential committee hearings, markups, and eventual floor consideration; any enacted version would then need passage by both House and Senate and signature by the President.

Considerations for Review

  • Budget impact: Procurement costs, ongoing stocking, and training expenses for BOP.
  • Implementation: Determination of stock levels, placement within facilities, and protocols for use.
  • Oversight: How compliance would be monitored and reported.

This summary captures the bill’s core aim and the likely areas affected, based on the provided text. For a detailed understanding, the committee report and any enacted language would provide specific provisions, definitions, and implementation guidance.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.